Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Affect Disord. 2021 Jun 7;292:500–507. doi: 10.1016/j.jad.2021.05.107

Table 1:

Demographic and clinical characteristics of the participants.

MDD
(n=110)
Healthy Controls
(n=27)
Psych Controls
(n=23)
P Value
Age, mean (sd) 19.5 (0.4) 20.3 (0.2) 19.1 (0.4) <0.006
Female, n (%) 72 (65) 10 (37) 10 (43) <0.010
White Race, n (%) 89 (86) 24 (89) 20 (87) >0.90
Hispanic, n (%) 9 (9) 2 (7) 3 (9) >0.90
Vaginal delivery, n (%) 76 (78) 21 (91) 17 (74) >0.30
Overweight/Obese, n (%) 26 (24) 9 (33) 8 (35) >0.50
Antibiotic use, n (%) 8 (7) 2 (7) 1 (4) >0.90
Alcohol Use, n (%) 86 (83) 17 (63) 16 (70) <0.060
MDD Status, n (%) <0.0001
In Episode 66 (60) 0 0
In Remission 44 (40) 0 0
Never 0 27 (100) 23 (100)
Taking SSRI, n (%) 43 (39) 0 3 (13) <0.0001
Trajectory Group, n (%) <0.0001
1 20 (19) 27 (100) 21 (95)
2 16 (15) 0 1 (5)
3 47 (45) 0 0
4 21 (20) 0 0

MDD: major depressive disorder, Psych Controls: psychiatric controls.

Missing data: Race (6), Ethnicity (6), Vaginal Delivery (16), Trajectory Group (7), Alcohol Use (6)

“Antibiotic Use” relates to use within 6 to 12 months prior to study entry, given that use within the past 6 months led to exclusion.

Trajectory group 1) participants with no depressive symptoms, 2) participants with low-level depressive symptoms, 3) participants in episode, remitting during the course of the study, and 4) participants persisting in episode during the course of the study.

sd= standard deviation